Foreign business intelligence GBI Research in a recent report that in 2021 the global market for multiple myeloma therapy in 2014 from the $ 7.3 billion increase to $ 8.9 billion, a CAGR (Compound Annual Growth Rate, CAGR) more moderate, at 4.6%.

GBI Research's report, the growth of multiple myeloma therapy market, mainly in the following eight regional markets, namely the United States, Britain, France, Germany, Italy, Spain, Japan, Canada, the main drivers of growth in population aging exacerbate brought ever increasing incidence of Zhang.

Drugs currently on the market such as Celgene's Revlimid (lenalidomide), with annual sales of $ 4.9 billion. With the approval of new drugs to market, multiple myeloma therapy market will be able to add, will provide alternative therapies to improve patients, to a certain extent, also contributed to the growth in this therapeutic area market.

Promising drug candidates include Takeda (Takeda) ixazomib oral drugs in late stage drug development company ArraryBiopharma America's filanesib, Bristol-Myers Squibb / Abbvie (BMS / AbbVie) of elotuzumab, Janssen (Janssen) of daratumumab

Yasser from GBI Research senior analyst of Mushtaq said that despite the current multiple myeloma can not be cured, but people at the level of cellular and molecular biology have a deeper understanding of its mechanism, and promote research in the field of innovative therapies for the treatment of progress in such clinical outcome can be significantly improved.

Some drugs in late-stage R & D pipeline will not have a significant impact on the entire market, but some drugs have been demonstrated in a special patient population encouraging clinical trial results, including elotuzumab from BMS / AbbVie and daratumumab from Janssen's, these drugs are expected to provide more choices for patients on therapy. However, a variety of market barriers (such as a limited number of target patients), multiple myeloma therapy will limit further growth in the market.

Mushtaq explained that, on the one hand because of its rare multiple myeloma rather be identified as an orphan disease, the number of patients is limited within a certain range, hindering the potential growth in this area of the market.On the other hand the cost of expensive drugs to slow the pace of research and development pharmaceutical companies to invest in this therapeutic area. But the government encourages multiple myeloma drug development for multiple myeloma drugs from other therapeutic areas, can promote the development of the treatment field to some extent.